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Discovering disease pathways, which can be defined as sets of proteins associated with a given dis-
ease, is an important problem that has the potential to provide clinically actionable insights for dis-
ease diagnosis, prognosis, and treatment. Computational methods aid the discovery by relying on
protein-protein interaction (PPI) networks. They start with a few known disease-associated proteins
and aim to find the rest of the pathway by exploring the PPI network around the known disease pro-
teins. However, the success of such methods has been limited, and failure cases have not been well
understood. Here we study the PPI network structure of 519 disease pathways. We find that 90%
of pathways do not correspond to single well-connected components in the PPI network. Instead,
proteins associated with a single disease tend to form many separate connected components/regions
in the network. We then evaluate state-of-the-art disease pathway discovery methods and show that
their performance is especially poor on diseases with disconnected pathways. Thus, we conclude that
network connectivity structure alone may not be su cient for disease pathway discovery. However,
we show that higher-order network structures, such as small subgraphs of the pathway, provide a
promising direction for the development of new methods.
Keywords: disease pathways, disease protein discovery, protein-protein interaction networks
1. Introduction
Computational discovery of disease pathways aims to identify proteins and other molecules associ-
ated with the disease.1–3 Discovered pathways are systems of interacting proteins and molecules that,
when mutated or otherwise altered in the cell, manifest themselves as distinct disease phenotypes
(Figure 1A).4 Disease pathways have the power to illuminate molecular mechanisms but their dis-
covery is a challenging computational task. It involves identifying all disease-associated proteins,2,5,6
grouping the proteins into a pathway,7–10 and analyzing how the pathway is connected to the disease
at molecular and clinical levels.11,12 Many of the main challenges facing the task arise from the inter-
connectivity of a pathway’s constituent proteins.2,13–15 This interconnectivity implies that the impact
of altering one protein is not restricted only to the altered protein, but can spread along the links of
the protein-protein interaction (PPI) network14 and a ect the activity of proteins in the vicinity.4,15
As understanding each disease protein in isolation cannot fully explain most human diseases, nu-
merous computational methods were developed to predict which proteins are associated with a given
disease, and to bring them together into pathways using the PPI network (Figure 1B).2,5–10,16,17 These
methods have accelerated the understanding of diseases, but have not yet fully succeeded in providing
actionable knowledge about them.1 For example, recent studies5,7,18 found that only a relatively small
fraction of disease-associated proteins physically interact with each other, suggesting that methods,
which predict disease proteins by searching for dense clusters/communities of interacting proteins
in the network, may be limited in discovering disease pathways. Analytic methods may thus be hin-
dered by such issues, and unless specifically tuned, can lead to an expensive and time-consuming hunt
for new disease proteins. Furthermore, although numerous methods exist, protein-protein interaction
and connectivity patterns of disease-associated proteins remain largely unexplored.4,12 Because of the
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Fig. 1. Network-based discovery of disease proteins. A Proteins associatedwith a disease are projected onto
the protein-protein interaction (PPI) network. In this work, disease pathway denotes a (undirected) subgraph of
the PPI network defined by the set of disease-associated proteins. The highlighted disease pathway consists of
five pathway components.BMethods for disease protein discovery predict candidate disease proteins using the
PPI network and known proteins associated with a specific disease. Predicted disease proteins can be grouped
into a disease pathway to study molecular disease mechanisms.
huge potential of these methods for the development of better strategies for disease prevention, diag-
nosis, and treatment, it is thus critical to identify broad conceptual and methodological limitations
of current approaches.
Present work.Herewe study the PPI network structure of 519 diseases. For each disease, we consider
the associated disease proteins and project them onto the PPI network to obtain the disease pathway
(Figure 1A).1,4 We then investigate the network structure of these disease pathways.a
We show that disease pathways are fragmented in the PPI network with on average more than 16
disconnected pathway components per disease. Furthermore, we find that each component contains
only a small fraction of all proteins associated with the disease. Through spatial analysis of the PPI
network we find that proximity of disease-associated proteins within the PPI network is statistically
insignificant for 92% (476 of 519) diseases, and that 90% of diseases are associated with proteins
that tend not to significantly interact with each other, indicating that disease proteins are weakly
embedded—rather than densely interconnected—in the PPI network.
We then consider state-of-the-art network-based methods for disease protein discovery (Fig-
ure 1B). These methods use the PPI network and a small set of known disease proteins to predict new
proteins that are likely associated with a given disease. However, as we show here, current methods
disregard loosely connected proteins when making predictions, causing many disease pathway com-
ponents in the PPI network to remain unnoticed. In particular, we find that performance of present
methods is better for diseases whose pathways have high edge density, are primarily contained within
a single pathway component, and are proximal in the PPI network. However, our analysis shows that
a vast majority of disease pathways does not display these characteristics.
The search for a solution to the better characterization of disease pathways has led us to study
higher-order protein-protein interaction patterns4,19–21 of disease proteins. Following on from earlier
work22 showing that higher-order PPI network structure around cancer proteins is di erent from the
structure around non-cancer proteins, we find that many proteins associated with the same disease are
involved in similar higher-order network patterns, even if disease proteins are not adjacent in the PPI
network. In particular, we find that proteins associated with 60% (310 of 519) of diseases do exhibit
aAll data and supplementary tables with results are at: http://snap.stanford.edu/pathways.
over-representation for certain higher-order network patterns, suggesting that disease proteins can
take on similar structural roles, albeit located in di erent parts of the PPI network. We demonstrate
that taking these higher-order network structures into account can shrink the gap between current
and goal performance of disease protein discovery methods.
In addition to new insights into the PPI network connectivity of disease proteins, our analysis on
network fragmentation of disease proteins and their distinctive higher-order PPI network structure
leads to important implications for future disease protein discovery that can be summarized as:
• We move away from modeling disease pathways as highly interlinked regions in the PPI network
to modeling them as loosely interlinked and multi-regional objects with two or more regions dis-
tributed throughout the PPI network.
• Higher-order connectivity structure provides a promising direction for disease pathway discovery.
2. Background and related work
Next, we give background on disease pathways and on methods for disease protein prediction.
Disease pathways. Broadly, a disease pathway in the PPI network is a system of interacting proteins
whose atypical activity collectively produces some disease phenotype.3,4,12,16 Given the PPI network
G = (V,E), whose nodes V represent proteins and edges E denote protein-protein interactions, the
disease pathway for disease d is an undirected subgraph Hd = (Vd, Ed) of the PPI network specified
by the set of proteins Vd that are associated with d, and by the set of protein-protein interactions Ed =
{(u, v)|(u, v) 2 E and u, v 2 Vd} (e.g., Adrenal cortex carcinoma pathway in Figure 4). To measure
the specifics of protein interactions within and outside the pathway we define pathway boundary as
the set Bd = {(u, v)|(u, v) 2 E, u 2 Vd, v 2 V \ Vd} consisting of all edges that have one endpoint
inside Hd and the other endpoint outside Hd.
Network-based methods for disease protein discovery. Given a specific disease, the task is to take
the PPI network and the disease proteins and to predict new proteins that are likely associated with
the disease. Approaches for this task are known as protein-disease association prediction or disease
module detection methods (Figure 1B), and can be grouped intro three categories. (1) Neighborhood
scoring and clustering methods4,5,7,9,10,12 assume that proteins that belong to the same network clus-
ter/community are likely involved in the same disease. In direct neighborhood scoring, each protein
is assigned a score that is proportional to the percentage of its neighbors associated with the disease.
To identify clusters that extend beyond direct neighbors, the methods start with a small set of disease
proteins (seed proteins) and grow a cluster by expanding the seeds with the highest scoring proteins.
However, few existing methods (e.g., connectivity significance-based method DIAMOnD) can work
with seed proteins that are not adjacent in the PPI network.7 (2) Di usion-based methods5,8,23 use
seed proteins to specify a random walker that starts at a particular seed protein and at every time
step moves to a randomly selected neighbor protein. Upon convergence, the frequency with which
the nodes in the network are visited is used to rank the corresponding proteins. (3) Representation
learning methods,6,16,17,21,24 such as matrix completion, graphlet degree signatures, and neural em-
beddings, construct representations for proteins (i.e., latent factors, embeddings) that capture known
protein-disease associations and/or proteins’ network neighborhoods, and then use these representa-
tions as input to a downstream predictor. We consider a neural embedding approach24 that first learns
a vector representation for each protein using a single-layer neural network and random walks and
then fits a logistic regression classifier that predicts disease proteins based on these feature vectors.
We also consider a matrix completion method6 that factorizes a protein-disease association matrix
into a set of protein and a set of disease latent factors while also incorporating the PPI network.
Predictions for a new disease are obtained as a function of the feature and latent factors.
Although many methods exist for predicting disease proteins, surprisingly little is known about
the PPI network structure of disease pathways and how it relates to the power of these methods.
3. Data
We continue by describing the datasets used in this study.
Human protein-protein interaction network.We use the human PPI network compiled byMenche
et al.18 and Chatr-Aryamontri et al..25 Culled from 15 databases, the network contains physical inter-
actions experimentally documented in humans, such as metabolic enzyme-coupled interactions and
signaling interactions. The network is unweighted and undirected with n = 21,557 proteins andm =
342,353 experimentally validated physical interactions. Proteins are mapped to genes and the largest
connected component of the PPI network is used in the analysis. We also investigate two other PPI
network datasets to make sure that our findings are not specific to the version of the PPI network
we are using. Unless specified, results in the paper are stated with respect to the first dataset. The
other two PPI networks are from the BioGRID database25 and the STRING database.26 Both of these
networks are restricted to those edges that have been experimentally verified.
Protein-disease associations.A protein-disease association is a tuple (u, d) indicating that alteration
of protein u is linked to disease d. Protein-disease associations are pulled from DisGeNET, a plat-
form that centralized the knowledge on Mendelian and complex diseases.2 We examine over 21,000
protein-disease associations, which are split among the 519 diseases that each has at least 10 disease
proteins. The diseases range greatly in complexity and scope; the median number of associations per
disease is 21, but the more complex diseases, e.g., cancers, have hundreds of associations.
Disease categories. Diseases are subdivided into categories and subcategories using the Disease
Ontology.27 The diseases in the ontology are each mapped to one or more Unified Medical Language
System (UMLS) codes, and of the 519 diseases pulled from DisGeNET, 290 have a UMLS code that
maps to one of the codes in the ontology. For the purposes of this study, we examine the second-level
of the ontology; this level consists of 10 categories, such as cancers (68 diseases), nervous system
diseases (44), cardiovascular system diseases (33), and immune system diseases (21).
Altogether, we use human disease and PPI network information that is more comprehensive than
in previous works,7,18,22 which focused on smaller sets of diseases and proteins.
4. Connectivity of disease proteins in the PPI network
We start by examining the network connectivity of disease proteins. We then analyze disease protein
discovery methods and contextualize their performance using disease pathway network structure.
4.1. Proximity of disease proteins in the PPI network
We begin by briefly describing network measures that we use to characterize connectivity of disease
proteins, both within disease pathways and with respect to the rest of proteins in the PPI network.
PPI network distance and concentration measures. We consider the following measures to char-
acterize PPI connectivity of disease proteins for each disease d and its associated pathway Hd:
• Size of largest pathway component: Fraction of disease proteins that lie in Hd’s largest pathway
component (i.e., the relative size of the largest connected component (LCC) of Hd).
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Fig. 2. Protein interaction connectivity of disease pathways. The distribution of (A) the network densities
of each disease pathway, (B) the relative size of the largest pathway component calculated as a fraction of
disease proteins that lie in the largest pathway component, and (C) the average shortest path length between
disparate pathway components in the PPI network.
• Density of the pathway: It is calculated as: 2|Ed|/(|Vd|(|Vd| 1)) and takes values in [0, 1]. A higher
density indicates a higher fraction of edges (out of all possible edges) appear between nodes inHd.
• Distance of pathway components: For each pair of pathway components (Figure 1A), we calculate
the average shortest path length between each set of proteins, and then, the average of this is taken
over all pairs of the components.
• Conductance:28 It is calculated as: |Bd|/(|Bd| + 2|Ed|) and takes values in [0, 1]. A lower conduc-
tance indicates the pathway is a more well-knit community separated from the rest of the network.
• Spatial network association:29,30 It measures concentration/localization of disease proteins in the
PPI network by quantifying how strongly disease proteins co-cluster within the PPI network and
whether this co-clustering is stronger than expected by random chance. It is calculated as:Kd(s) =
2/(p¯n)2
P
i pi
P
j(pj p¯)I(`G(i, j) < s),where pi is a binary indicator indicating if node i represents
a d-associated protein, p¯ = 1/n
P
i pi, and I(`G(i, j) < s) equals 1 if the shortest path length
between i and j is less than s and 0 otherwise. If all disease proteins lie in one PPI network region,
most of them are found for small values of s, while for uniformly spread proteins in the PPI network
Kd(s) achieves larger values only for large values of s. The significance of Hd’s concentration is
determined by computing the area under theKd(s) curve29 for d-associated proteins and comparing
it to curves obtained by applying the same statistic to sets of random proteins.
• Network modularity:31 Fraction of edges that fall within/outside the pathway minus the expected
fraction if edges were randomly distributed: Qd = 1/(2m)
P
ij(I((i, j) 2 E)  kikj2m ) (pi, pj), where
ki is the degree of i, and  (pi, pj) is 1 if pi and pj are equal and 0 otherwise.
PPI network structure of disease pathways. First, we find that disease pathways are fragmented
in the PPI network, with a median of 16 connected components per disease and a median of only
21% of the proteins lying in the largest pathway component (Figure 2A). Only approximately 10% of
pathways have over 60% of their proteins in the largest pathway component. We also find that disease
pathways are not particularly well connected internally with only a median density of 0.07 (the overall
PPI network density is 0.0015), and 90% of diseases have a density below 0.17 (Figure 2B). Further-
more, they are rather well connected externally, having a median conductance of 0.96, meaning that
the disease pathway has relatively as many edges pointing outside the pathway to the rest of the PPI
network as it has edges lying inside the pathway. The median distance between the pathway compo-
nents is almost 2.9 (Figure 2C). These results counter expectations as they show that disease pathways
do not have the PPI network structure one expects of a traditional network cluster/community, which
is well connected internally and has few edges pointing outside the cluster.14,31
A B 
D
is
ea
se
 p
at
hw
ay
s
Network modularity [log10(value)]Spatial network association [-log10(p-value)]
D
is
ea
se
 p
at
hw
ay
s
Diamond-blackfan
anemia
Stomach 
neoplasms
Leigh syndrome
Glioblastoma
Myeloid leukemia
Prostatic
neoplasms
Liver 
carcinoma
Lung neoplasms
Diabetes mellitus
Mitochondrial 
complex I deficiency
Oxidoreductase
deficiency
Mammary
neoplasms
Williams
syndrome
Dementia
Kartagener
syndrome
Fig. 3. Spatial clustering and modular structure of disease pathways in the PPI network. The distribu-
tion of (A) the spatial clustering calculated for each disease pathway as the strength of association29 between
the set of disease proteins and the PPI network (shaded area indicates significant spatial clustering at ↵ = 0.05
level), and (B) the modularity31 of disease pathways in the PPI network.
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Fig. 4. Disease pathways in the wider PPI network. A small PPI subnetwork highlighting physical interac-
tions between disease proteins associated with (A) Mitochondrial complex I deficiency, (B) Noonan syndrome,
(C) Cholangiocarcinoma, and (D) Adrenal cortex carcinoma. Shown are selected disease pathways whose spa-
tial clustering29 within the PPI network is statistically significant (p-values shown; entire distribution of the
p-values is shown in Figure 3A) and is also among the strongest (top-30 diseases) in the disease corpus.
To statistically test how well disease pathways are localized in the PPI network, we conduct spa-
tial analysis of the PPI network. We find no significant pathway localization for 92% of diseases
(Figure 3A), suggesting that these diseases have pathways that are multi-regional with two or more
regions of disease proteins in di erent parts of the PPI network. The presence of multiple regions
suggests that each disease might be comprised of several groups of proteins that are located in weakly
connected or disconnected regions of the PPI network and thus may be functionally distinct.1,4 We
find that only 43 of 519 (8%) diseases are region-specific (examples in Figure 4), i.e., they signif-
icantly associate with only one local neighborhood and can be found in a single region of the PPI
network. We also observe that the number of edges within a disease pathway rarely exceeds the num-
ber expected on the basis of chance (Figure 3B). The median modularity of disease pathways is only
4.6⇥10 4, reflecting there is no significant concentration of edges within disease pathways compared
with random distribution of edges between all proteins regardless of pathways. These results suggest
that integration of disconnected regions of disease proteins into a broader disease pathway will be
crucial for a holistic understanding of disease mechanisms.
Finally, we note that these findings can be reproduced in three PPI network datasets (Section 3),
suggesting that our key results are robust against potential biases in the PPI network data.
4.2. Connections between PPI network structure and disease protein discovery
Next, we study disease protein discovery methods based on some of the most frequently used prin-
ciples for identifying disease proteins,14 and evaluate them through PPI pathway network structure.
Methods and experimental setup. We consider five methods: direct neighborhood scoring,5 neu-
ral embeddings,24 matrix completion,6 network di usion,8,23 and connectivity significance (DIA-
MOnD).7 See Section 2 for details on the methods. We use disease-centric ten-fold cross-validation.
For each disease, the set of all proteins is randomly split into ten folds, with each fold containing an
equal number of proteins associated with that disease. In each of the ten runs, the goal is to predict
disease proteins in the test fold, assuming knowledge of disease proteins in the nine other folds. Each
method assigns a score to each protein in the network representing the probability that the protein is
associated with the disease. 20 diseases are set aside for hyperparameter selection, and the remaining
499 are used for testing. For evaluation, recall-at-k is measured to quantify what fraction of all the
disease proteins are ranked within the first k predicted proteins (e.g., k = 25, 100). We also calculate
the mean reciprocal rank (MRR) for all of the algorithms in order to get an overall measure of method
performance. Measures range between 0 and 1, and a higher score indicates better performance.
Prediction performance in the context of disease pathway structure. Figure 5 shows performance
of disease protein discoverymethods as a function of PPI connectivity of disease proteins.We observe
that the higher the degree of agglomeration of disease proteins within the PPI network, the higher
the performance of prediction methods. In particular, across all five methods, performance correlates
positively with density and percent of proteins in the largest pathway component, and negatively with
the distance between pathway components. These correlations are weaker for the Neural embeddings
than for the other four methods, but the overall direction of the trends is the same across all of them.
For example, the correlation between density and recall-at-100 is ⇢ = 0.45 for the Neural embeddings
and between ⇢ = 0.54 and ⇢ = 0.63 for the other four methods (Figure 5B).
Across all diseases, random walk-based methods are the best performers, as evaluated by both
mean reciprocal rank (MRR = 0.061 and MRR = 0.050 for Random walk and Neural embeddings,
respectively) and recall (Recall-at-100 = 0.356 and Recall-at-100 = 0.300 for Random walk and Neu-
ral embeddings, respectively). However, we see that Random walk method is particularly dependent
on the percent of disease proteins in the largest pathway component (Figure 5A). The di erence in
recall between the Random walk method and the Neural embeddings is positively correlated (⇢ =
0.26) with that percentage. Since random walks and other di usion-based variants are very popular,
it is problematic that they are reliant on properties that are not typical of disease pathways.
Neighborhood scoring performs the worst by bothmetrics (MRR= 0.029, Recall-at-100 = 0.242).
The superior performance of random walk-based methods indicates that the assumption that the
neighborhood method makes in calculating scores based only on protein’s neighbors is too restrictive
when defining disease locality.5 Though DIAMOnD does not outperform Random walk, we observe
that it has a comparable recall in its higher-ranked predictions (recall-at-25 = 0.186, compared to
Random walk’s 0.199), but its performance lags considerably for lower-ranked predictions (Recall-
at-100 = 0.300, compared to Random walk’s 0.356).
We see the most complementarity between Neural embeddings, Matrix completion and the other
methods, which makes sense given that the other three methods are all based on direct/indirect net-
work neighborhood scoring, while Neural embeddings and Matrix completion more flexibly capture
Neighborhood Random walk DIAMOnD Neural embeddings Matrix completion
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Fig. 5. Prediction quality versus PPI connectivity of disease proteins. Each point represents one disease;
its location is determined by the quality of predicted disease proteins (y-coordinate), and by the connectivity
of disease proteins in the PPI network (x-coordinate). Across all five methods, the trends uniformly indicate
that (A) the bigger the largest pathway component, (B) the more densely interconnected the disease pathway,
and (C) the lower the average shortest path length between disparate pathway components, the better the pre-
dictions. The shaded areas represent the space in which 95% (494 of 519) of all diseases reside.
network structure and neighborhoods of disease proteins.6 For example, we can examine the disease
pathway for Juvenile myelomonocytic leukemia in which Neural embeddings method performs far
better than Random walk (Recall-at-100 = 0.550, compared to Random walk’s 0.200). The pathway
consists of nineteen nodes, but there exists only three edges within the pathway (network density =
0.008). Therefore, the Neural embeddings method is able to capture latent features about pertinent
nearby nodes that Randomwalk struggles to find, given that Randomwalk is highly dependent on the
edges near the seed proteins. On the other hand, the pathway for Squamous cell carcinoma is more
accurately detected by Random walk than by Neural embeddings (Recall-at-100 = 0.540, compared
to Neural embeddings’ 0.120). This can be explained by higher interconnectivity of Squamous cell
carcinoma pathway in the PPI network (network density = 0.034) suggesting that there are advantages
to focusing on local edge connectivity.
Performance variation across disease categories. We observe strong di erences in performance
across disease categories indicating that diseases should not be considered as a monolithic category,
given the very di erent mechanisms behind them. The same performance patterns hold across all five
of the methods, suggesting that none of the assumptions each method makes about pathway structure
correspond to any of the particular mechanisms that tend to be more specific to one disease category.
Furthermore, because of the similar performance among methods over easy32 (e.g., median recall-
at-100 = 0.720 for Mendelian diseases) and di cult32 (e.g., median recall-at-100 = 0.360 for cancer
diseases) disease categories, the assumptions made by current methods do not seem to accurately
reflect the uncertainty associated with a protein’s true association with a disease.
5. Higher-order connectivity of disease proteins in the PPI network
We showed in Section 4 that proximity of disease proteins in the PPI network is likely insu cient
for the disease protein discovery task as disease pathways have rather low PPI density and a rather
high conductance. To look past just edge connectivity for the prediction of disease proteins, we in-
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vestigate what higher-order PPI network structures disease proteins are likely to be involved in, and
then incorporate this structure information to augment prediction capability of current methods.
Motif signatures of disease proteins. The analysis of higher-order PPI network structure can be
formalized by counting network motifs, which are subgraphs that recur within a larger network. We
here focus on graphlets,19,20,22,33 connected non-isomorphic induced subgraphs (examples shown in
Figure 6). There are 30 possible graphlets of size 2 to 5 nodes. The simplest graphlet is just two nodes
connected by an edge, and the most complex graphlet is a clique of size 5. By taking into account
the symmetries between nodes in a graphlet, there are 73 di erent positions or orbits for 2–5-node
graphlets, numerated from 0 to 72. For each node in the PPI network we count the number of orbits
that the node touches. Motif signature of a protein is thus a set of 73 numbers, hi (i = 0, 1, . . . , 72)
representing the number of induced subgraphs the corresponding node is in, in which the node took
the i-th orbital position. We use this signature to represent protein’s higher-order connectivity in the
PPI network.
We conduct permutation tests, comparing the median of the orbit distribution values for proteins
associated with a given disease to the medians for 5,000 random samples of sets of proteins of the
same size as the disease pathway. These values are used to calculate p-values for each disease at each
orbit position. An orbit position for a disease is considered significant if there is an over-representation
of counts in the disease proteins compared to the 99% of random samples (i.e., ↵ = 0.01).
Characterization of motifs around disease proteins. We find that there is a characteristic higher-
order PPI network structure around disease proteins (Figure 6), indicating that disease proteins dis-
play significance in terms of the orbit positions they tend to inhabit, which could point towards the
underlying mechanisms they participate in. We see that 60% (310 of 519) of diseases do show orbit
signatures that di er from background proteins and are significantly greater than what one would
expect at random. Therefore, even though proteins associated with these diseases may not be adja-
cent in the PPI network, the diseases do show overall over-representation for certain orbit positions
indicating that proteins in disease pathway may take on similar structural roles, albeit in non-adjacent
regions in the PPI network.
We can note that orbit position 0 corresponds to subgraphs of two nodes (only an edge), 1 through
Table 1. Examples of disease-associated motifs. Shown are 6 orbits (orbit position, i.e., the location where
the node touches the motif, is shown in red) whose over-representation is found in most diseases.
Significant orbit # of diseases Examples of diseases with significant orbits
78 Neoplastic cell transformation, Celiac disease, Non-small cell lungcarcinoma, Squamous cell carcinoma, Prostatic neoplasms
62 Neoplastic cell transformation, Stomach neoplasms, Restless legssyndrome, Celiac disease, Prostatic neoplasms
62 Neoplastic cell transformation, IGA glomerulonephritis, Precancerousconditions, Prostatic neoplasms, Liver neoplasms
88 Peroxisome biogenesis disorders, Crohn disease, Mitochondrialencephalomyopathies, Venous thromboembolism, Myopia
229 Amphetamine-related disorders, Mitochondrial myopathies,Cocaine-related disorders, Nuclear cataract, Polycystic ovary syndrome
228 Amphetamine-related disorders, Leber congenital amaurosis,Craniofacial abnormalities, Hyperalgesia, Respiratory hypersensitivity
3 correspond to subgraphs of three nodes, 4 through 14 correspond to subgraphs of four nodes, and
the rest correspond to induced subgraphs of five nodes. Therefore, although the distribution of smaller
subgraphs such as nodes and triangles are not significant in many diseases, almost 50% of diseases
have disease pathways that contain proteins that are over-represented for the most complex orbit po-
sitions. For example, orbit position 14 is statistically significantly over-represented in approximately
50 diseases, and position 72 is in over 200 of the diseases (Figure 6, examples in Table 1). We note
that we also statistically test for under-representation of the orbit counts, no statistically significant
results are observed.
Characterization of motifs for disease categories. We also want to investigate whether the orbit
signatures are characteristic of diseases in general, or whether there are also di erences that could
be attributed back to the category the disease belongs to. In order to test this, for each of the 73
orbit positions and for each disease category, we find the statistical significance of the di erence in
distributions using a two-sample Kolmogorov-Smirnov test. The first sample consists of all the orbit
counts for the proteins that are found in at least one disease in a given category, and the other sample
consists of all the orbit counts for the proteins that are not associated with any disease in the category.
After applying the Bonferroni correction, we then consider a p-value of ↵ = 0.01 to be significant.
We find that the most significant di erences tend to occur in the more complex motifs. Ta-
ble 2 shows orbit positions that are considered most characteristic for each disease category, and the
graphlets they appear in, which could indicate inherent di erences in the manifestations of di erent
classes of diseases.
6. Prediction of disease proteins using higher-order PPI network structure
Higher-order PPI network structure is generally not taken into account in current disease protein
discovery, although, as showed in Section 5, this structure does encode distinct information about
disease proteins. Earlier work showed that motif signatures provide useful signal for biological func-
tion prediction,22,33 but here we want to examine whether they provide additional signal past what
edge connectivity in the PPI network already contributes, and if they specifically work for disease
protein discovery task.
Setup and results. We conduct a logistic regression experiment in which we augment the Neural
Table 2. Characteristic motifs for disease categories. Shown are 5 orbits whose over-representation is found
in most diseases belonging to a disease category. The orbit position of a node is marked in red.
Disease category Significant orbits Orbit positions
Urinary system diseases e.g.,
Hyperhomocysteinemia, Nephrosis 26, 20, 33, 30, 47
Acquired metabolic diseases e.g.,
Methylmalonic acidemia, Hyperinsulinism 23, 33, 44, 7, 48
Monogenic diseases e.g., Marfan
syndrome, Bardet-Biedl syndrome 20, 30, 11, 42, 58
Cancer e.g., Tumor of salivary gland,
Papillary thyroid carcinoma 33, 23, 30, 21, 61
Gastrointestinal system diseases e.g.,
Eosinophilic esophagitis, Oral fibrosis 3, 11, 2, 44, 16
Inherited metabolic disorders e.g., Leigh
disease, Mitochondrial complex deficiency 33, 2, 30, 42, 44
Immune system diseases e.g., Deficiency
syndromes, Hypersensitivity 33, 7, 11, 42, 44
Musculoskeletal system diseases e.g.,
Muscular atrophy, Muscular dystrophy 23, 13, 11, 42, 26
Nervous system diseases e.g., Peripheral
neuropathy, Nerve degeneration 33, 7, 11, 23, 26
Cardiovascular system diseases e.g.,
Dilated cardiomyopathy, Tachycardia 58, 14, 11, 48, 67
embeddings (Section 4.2) with information about motif signatures (Section 5). In particular, for each
protein we concatenate its neural embeddingwith its motif signature. Instead of using themotif signa-
ture directly, we concatenate the embedding with h0, where h0i = max(0, log(hi)), for i = 0, 1, . . . , 72.
We find that neural embeddings augmented by motif signatures performed on average 11% better
than neural embeddings alone (Recall-at-100 = 0.332, compared to Neural embeddings’ 0.300). For
example, in the case of Hearing loss, the disease that has the greatest increase in performance after
the inclusion of higher-order structure, we observe that the recall-at-100 jumps from 0.03 to 0.77 (and
the recall-at-100 is at most 0.10 for the four other prediction methods in Section 4.2). If we examine
the signature of Hearing loss, as calculated in Section 5, we see that the Hearing loss pathway is
significant across all 73 orbit positions, meaning it has a particularly unique signature compared
to the background distribution. Though such improvement in performance is not typical across all
diseases, this analysis identifies the opportunity to systemically identify diseases which are likely to
benefit the most from the inclusion of higher-order PPI network information.
7. Conclusion
The overall goal of network biology is to develop approaches that use genomic and other network
information to better understand human disease. Given the complexity of this goal, we focused on
studying the PPI network structure of disease pathways, defined through sets of proteins associated
with diseases. We found that disease pathways are fragmented and sparsely embedded in the PPI net-
work, and that spatial clustering of disease pathways within the PPI network is statistically insignif-
icant. To better understand broad caveats of current methodology for disease protein discovery we
evaluated the performance of leading methods and found that their assumptions do not fully capture
PPI network structure. We showed, however, that there is detectable higher-order PPI network struc-
ture around disease proteins that can be leveraged to boost algorithm performance. These findings
provide new insights into the disease pathway PPI network structure and can guide methodological
advances in disease protein discovery.
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